| Symbol | AUTL |
|---|---|
| Name | AUTOLUS THERAPEUTICS PLC |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 191 WOOD LANE,THE MEDIAWORKS, LONDON, W12 7FP, United Kingdom |
| Telephone | +44 2038296230 |
| Fax | — |
| — | |
| Website | https://www.autolus.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. The companys clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Additional info from NASDAQ: |
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read moreNew Form DEL AM - Autolus Therapeutics plc <b>Filed:</b> 2026-04-15 <b>AccNo:</b> 0001193125-26-155644 <b>Size:</b> 44 KB
Read moreAutolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Read moreNew Form 3 - Autolus Therapeutics plc <b>Filed:</b> 2026-03-23 <b>AccNo:</b> 0002054449-26-000005 <b>Size:</b> 4 KB
Read moreAutolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026
Read moreNew Form SCHEDULE 13G/A - Autolus Therapeutics plc <b>Filed:</b> 2026-02-17 <b>AccNo:</b> 0001172661-26-001258 <b>Size:</b> 10 KB
Read moreNew Form SCHEDULE 13G/A - Autolus Therapeutics plc <b>Filed:</b> 2026-02-13 <b>AccNo:</b> 0001019056-26-000041 <b>Size:</b> 20 KB
Read more